Get the Stockscreener App
4.78
1.85%
-0.09
After Hours:
4.86
0.08
+1.67%
Cellectar Biosciences Inc stock is traded at $4.78, with a volume of 39,193.
It is down -1.85% in the last 24 hours and down -0.42% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$4.87
Open:
$4.9
24h Volume:
39,193
Relative Volume:
0.00
Market Cap:
$8.66M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-1.4708
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
+0.00%
1M Performance:
-0.42%
6M Performance:
+1,632%
1Y Performance:
+145.13%
1-Day Range:
$4.75
$4.99
1-Week Range:
$4.4406
$5.15
52-Week Range:
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
4.78 | 13.91M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Cellectar Biosciences Inc. Shows Early Signs of Technical StrengthInvestment Plan With Growth Optimization Finalized - metal.it
Is it the right time to buy Cellectar Biosciences Inc. stockInvest in stocks with long-term growth potential - Jammu Links News
When is Cellectar Biosciences Inc. stock expected to show significant growthGet real-time updates on market trends - Jammu Links News
Is Cellectar Biosciences Inc. stock overvalued or undervaluedExtraordinary market timing - Jammu Links News
What makes Cellectar Biosciences Inc. stock price move sharplyExceptional profit velocity - Jammu Links News
Published on: 2025-08-03 14:24:10 - Jammu Links News
How does Cellectar Biosciences Inc. generate profit in a changing economyRapid wealth creation - Jammu Links News
What are analysts’ price targets for Cellectar Biosciences Inc. in the next 12 monthsRecord-setting profit potential - Jammu Links News
Is Cellectar Biosciences Inc. a growth stock or a value stockMaximize returns with strategic stock selection - Jammu Links News
Should I hold or sell Cellectar Biosciences Inc. stock in 2025Invest smarter with daily trading signals - Jammu Links News
What are the latest earnings results for Cellectar Biosciences Inc.Get professional advice for portfolio optimization - Jammu Links News
Why Cellectar Biosciences Inc. stock attracts strong analyst attentionStable Growth Stock Overview Signal - beatles.ru
Oragenics' Stock Takes A Hit With New Offering Announcement - Finimize
What’s the recovery path for long term holders of Cellectar Biosciences Inc.Market Momentum and Signal Alerts Suggest Reversal - metal.it
Cellectar Biosciences Inc.’s Price Action Aligns with Quant SignalsFree Stock Market Practical Discussion Forums - beatles.ru
How to recover losses in Cellectar Biosciences Inc. stockLow Risk Stock Selection Strategy Guide - Newser
How to manage a losing position in Cellectar Biosciences Inc.Day Trading Setup Forecast with Trend Model - Newser
Cellectar Biosciences Inc. Could See a Relief Rally From SupportExit Ready Momentum Stock Watchlist Expanded - metal.it
Screener Results Flag Cellectar Biosciences Inc. as OversoldConsistent Gain Investment Strategies Emerge - metal.it
Published on: 2025-07-29 16:45:28 - metal.it
How high can Cellectar Biosciences Inc. stock goWeekly Setup Summary for Risk Controlled Trades - Newser
Why did Cellectar's operating expenses surge in Q4 2024? - AInvest
Published on: 2025-07-29 04:25:46 - Newser
Technical analysis overview for Cellectar Biosciences Inc. stockSwing Candidate List with Trade Cues - Newser
Cellectar Biosciences Inc. Builds Base for Possible ReboundFast Exit and Entry Strategy Guide Offered - metal.it
Why is Cellectar Biosciences Inc. stock attracting strong analyst attentionExpert Picks Outlook To Watch Now - Jammu Links News
How to manage a losing position in Cellectar Biosciences Inc. Predictive Screener for Daily Trade Watch - Newser
What is Cellectar Biosciences Inc. company’s growth strategyBuild your wealth with consistent stock growth - Jammu Links News
Published on: 2025-07-27 20:39:48 - Jammu Links News
Intrinsic Value of Cellectar Biosciences Inc. Stock: Is It Undervalued or OvervaluedFree Professional Portfolio Management - Newser
How Cellectar Biosciences Inc. stock performs during market volatilitySmart Trading With Safety Margin - Newser
Cellectar Biosciences Inc. Stock Analysis and ForecastPhenomenal capital gains - PrintWeekIndia
What institutions are buying Cellectar Biosciences Inc. stock nowExplosive wealth accumulation - jammulinksnews.com
Is Cellectar Biosciences Inc. a good long term investmentConsistent triple returns - PrintWeekIndia
What drives Cellectar Biosciences Inc. stock priceMassive wealth growth - Autocar Professional
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):